Ad
Friday, 27 April 2018
Gilead's three-drug HIV regimen wins European panel approval
(Reuters) - Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment